Business Description
Oncolys BioPharma Inc
ISIN : JP3202170001
Total Employee Number:
45Description
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.88 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.8 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 80.87 | |||||
Beneish M-Score | 0.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -73 | |||||
3-Year EBITDA Growth Rate | -6.5 | |||||
3-Year EPS without NRI Growth Rate | -6 | |||||
3-Year FCF Growth Rate | 8.7 | |||||
3-Year Book Growth Rate | 3.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.74 | |||||
9-Day RSI | 40.37 | |||||
14-Day RSI | 44.2 | |||||
3-1 Month Momentum % | 0.73 | |||||
6-1 Month Momentum % | 48.17 | |||||
12-1 Month Momentum % | 290.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.12 | |||||
Quick Ratio | 5.11 | |||||
Cash Ratio | 4.04 | |||||
Days Sales Outstanding | 367.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.1 | |||||
Shareholder Yield % | -4.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2853.22 | |||||
Net Margin % | -2895.62 | |||||
EBITDA Margin % | -2876.43 | |||||
FCF Margin % | -6144.52 | |||||
OCF Margin % | -6134.99 | |||||
ROE % | -33.39 | |||||
ROA % | -27.49 | |||||
ROIC % | -131.72 | |||||
3-Year ROIIC % | 1092.97 | |||||
ROC (Joel Greenblatt) % | -340.96 | |||||
ROCE % | -31.64 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1992.83 | |||||
PB Ratio | 20.39 | |||||
Price-to-Tangible-Book | 20.38 | |||||
EV-to-EBIT | -77.38 | |||||
EV-to-EBITDA | -77.39 | |||||
EV-to-Revenue | 2226.25 | |||||
EV-to-FCF | -37.35 | |||||
Price-to-GF-Value | 6.88 | |||||
Price-to-Median-PS-Value | 52.1 | |||||
| Price-to-Net-Current-Asset-Value | 20.7 | |||||
| Price-to-Net-Cash | 28.16 | |||||
Earnings Yield (Greenblatt) % | -1.29 | |||||
FCF Yield % | -2.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncolys BioPharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 31.636 | ||
| EPS (TTM) (円) | -34.35 | ||
| Beta | 0.9727 | ||
| 3-Year Sharpe Ratio | 1.03 | ||
| 3-Year Sortino Ratio | 2.38 | ||
| Volatility % | 83.38 | ||
| 14-Day RSI | 44.2 | ||
| 14-Day ATR (円) | 175.63048 | ||
| 20-Day SMA (円) | 2674.25 | ||
| 12-1 Month Momentum % | 290.97 | ||
| 52-Week Range (円) | 570 - 3695 | ||
| Shares Outstanding (Mil) | 29.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncolys BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncolys BioPharma Inc Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncolys BioPharma Inc Frequently Asked Questions
What is Oncolys BioPharma Inc(TSE:4588)'s stock price today?
The current price of TSE:4588 is 円2501.00. The 52 week high of TSE:4588 is 円3695.00 and 52 week low is 円570.00.
When is next earnings date of Oncolys BioPharma Inc(TSE:4588)?
The next earnings date of Oncolys BioPharma Inc(TSE:4588) is .
Does Oncolys BioPharma Inc(TSE:4588) pay dividends? If so, how much?
Oncolys BioPharma Inc(TSE:4588) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Oncolys BioPharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers